Free Trial

TG Therapeutics (TGTX) Stock Price, News & Analysis

TG Therapeutics logo
$29.33 +0.37 (+1.28%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$29.37 +0.04 (+0.14%)
As of 08/29/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TG Therapeutics Stock (NASDAQ:TGTX)

Key Stats

Today's Range
$28.61
$29.47
50-Day Range
$26.39
$39.19
52-Week Range
$21.11
$46.48
Volume
1.82 million shs
Average Volume
2.91 million shs
Market Capitalization
$4.65 billion
P/E Ratio
79.27
Dividend Yield
N/A
Price Target
$46.25
Consensus Rating
Moderate Buy

Company Overview

TG Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

TGTX MarketRank™: 

TG Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 77th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    TG Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about TG Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for TG Therapeutics are expected to grow by 1,150.00% in the coming year, from $0.08 to $1.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TG Therapeutics is 79.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 271.12.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TG Therapeutics is 79.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.67.

  • Price to Book Value per Share Ratio

    TG Therapeutics has a P/B Ratio of 20.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about TG Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.53% of the float of TG Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    TG Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in TG Therapeutics has recently decreased by 3.02%, indicating that investor sentiment is improving.
  • Dividend Yield

    TG Therapeutics does not currently pay a dividend.

  • Dividend Growth

    TG Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.53% of the float of TG Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    TG Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in TG Therapeutics has recently decreased by 3.02%, indicating that investor sentiment is improving.
  • News Sentiment

    TG Therapeutics has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.11 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for TG Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    12 people have searched for TGTX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,400.00 in company stock.

  • Percentage Held by Insiders

    10.64% of the stock of TG Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about TG Therapeutics' insider trading history.
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TGTX Stock News Headlines

A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
See More Headlines

TGTX Stock Analysis - Frequently Asked Questions

TG Therapeutics' stock was trading at $30.10 at the beginning of the year. Since then, TGTX stock has decreased by 2.6% and is now trading at $29.33.

TG Therapeutics, Inc. (NASDAQ:TGTX) posted its earnings results on Monday, August, 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by $0.15. The firm's revenue was up 92.1% compared to the same quarter last year.
Read the conference call transcript
.

TG Therapeutics' top institutional investors include State Street Corp (4.80%), Geode Capital Management LLC (2.20%), Soleus Capital Management L.P. (1.41%) and Hood River Capital Management LLC (0.99%). Insiders that own company stock include Michael S Weiss, Sean A Power, Yann Echelard, Laurence N Charney and Sagar Lonial.
View institutional ownership trends
.

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TG Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/04/2025
Today
9/01/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TGTX
CIK
1001316
Employees
290
Year Founded
1993

Price Target and Rating

High Price Target
$55.00
Low Price Target
$37.00
Potential Upside/Downside
+57.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.37
Trailing P/E Ratio
79.27
Forward P/E Ratio
366.63
P/E Growth
N/A
Net Income
$23.38 million
Net Margins
13.31%
Pretax Margin
14.56%
Return on Equity
26.05%
Return on Assets
9.58%

Debt

Debt-to-Equity Ratio
0.89
Current Ratio
3.86
Quick Ratio
2.96

Sales & Book Value

Annual Sales
$329 million
Price / Sales
14.15
Cash Flow
$0.12 per share
Price / Cash Flow
244.49
Book Value
$1.43 per share
Price / Book
20.51

Miscellaneous

Outstanding Shares
158,670,000
Free Float
141,784,000
Market Cap
$4.65 billion
Optionable
Optionable
Beta
1.88

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:TGTX) was last updated on 9/1/2025 by MarketBeat.com Staff
From Our Partners